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Abstract
Background: Atrial fibrillation (AF) is a leading cause of fatal ischemic stroke. It was recently reported that
international normalized ratio (INR) levels were associated with infarct volumes. However, factors other than INR
levels that affect stroke phenotypes are largely unknown. Therefore, we evaluated the determinants of stroke
phenotypes (pattern and volume) among patients with AF who were not adequately anticoagulated.
Methods: We analyzed data pertaining to consecutive AF patients admitted over a 6-year period with acute MCA
territory infarcts. We divided the patients according to DWI (diffusion-weighted imaging) lesion volumes and
patterns, and the relationship between stroke predictors (the CHADS2 and CHA2DS2-VASc score), systemic, and
local factors and each stroke phenotype were then evaluated.
Results: The stroke phenotypes varied among 231 patients (admission INR median 1.06, interquartile range (IQR)
1.00-1.14). Specifically, (1) the DWI lesion volumes ranged from 0.04-338.62 ml (median 11.86 ml; IQR, 3.07-44.20 ml)
and (2) 46 patients had a territorial infarct pattern, 118 had a lobar/deep pattern and 67 had a small scattered
pattern. Multivariate testing revealed that the CHADS2 and CHA2DS2-VASc score were not related to either stroke
phenotype. Additionally, the prior use of antiplatelet agents was not related to the stroke phenotypes. Congestive
heart failure and diastolic dysfunction were not associated with stroke phenotypes.
Conclusions: The results of this study indicated that the determinants of stroke phenotypes were different from
the predictors (i.e., CHADS2 and CHA2DS2-VASc score) of stroke in patients with AF.
Background
Atrial fibrillation (AF) affects 3% to 5% of the population
older than 65 years of age [1] and is a leading cause of
fatal ischemic stroke [2,3]. Stroke in patients with AF is
generally more severe and the outcome is markedly poorer
than in patients with sinus rhythm [4]. Adjusted-dose war-
farin is highly effective (~60% reduction), and aspirin is
modestly effective (~20% reduction) for the prevention of
stroke in AF [5,6]. Moreover, international normalized
ratio (INR) levels at the time of stroke were recently
reported to be associated with infarct volumes [7].
However, the factors affecting stroke phenotypes are
unknown among AF patients. Several studies have sug-
gested that infarct patterns are better delineated by DWI
than other imaging modalities, are correlated with the
underlying stroke pathogenic mechanism,[8,9] and are
associated with stroke outcome [10]. In addition, the
infarct pattern on DWI may differ depending on the
characteristics (type and nature) of clots [11-13]. Risk
factors for stroke (the CHADS2 and CHA2DS2-VASc
score) and systemic (D-dimer and C-reactive protein)
and local (left ventricular ejection fractions) factors may
be associated with stroke phenotype. AF is associated
with higher levels of prothrombotic factors, endothelial
dysfunction, and markers of platelet activation [12,14,15].
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influenced by several hemodynamic factors that promote
stasis, each of which can fluctuate over time, and perhaps
also by mild prothrombotic hematological perturbations
that favour thrombosis [6]. Therefore, we evaluated the
determinants of stroke phenotypes (i.e., volume and pat-
tern) among patients with AF who were not adequately
anticoagulated (INR < 1.6) to identify factors besides the
INR level that may influence the phenotypic presentation
of stroke. The results presented here could lead to strate-
gies for the prediction of stroke extent and improve clini-
cal outcomes.
Methods
Patient selection
We analyzed demographic, clinical, laboratory, and radio-
graphic data collected prospectively from consecutive
patients admitted to Samsung Medical Centre for acute
cerebral infarction from January 2005 through June 2011.
Inclusion criteria for this study were: (a) presentation
within three days of the onset of symptoms, (b) acute
ischemic lesions within the MCA distribution on diffu-
sion-weighted imaging (DWI), and (c) AF diagnosed pre-
viously or detected during the admission period. The
exclusion criteria were: (a) patients who met the Trial of
Org 10172 in the Acute Stroke Treatment algorithm
competing diagnosis of large artery disease, small vessel,
or other causes, (b) patients who did not have INR deter-
mination and DWI performed within 12 hours of initial
presentation, and (c) patients who had INR levels greater
than 1.6 (achieving INRs distributed equally in the range
of 1.6 to 2.5 has been reported to provide 90% of the
protection of INRs between 2.0 and 3.0 for primary pre-
vention of stroke in patients with nonvalvular AF) [6].
The local Institutional Review Board approved the study
and informed consent was obtained from participants.
Work-up
All patients underwent MRI (3.0T, Achieva, Philips Medi-
cal Systems) using a protocol that also included DWI, gra-
dient-recalled echo, fluid-attenuated inversion recovery,
and magnetic resonance angiography (MRA) imaging of
the cervical and intracranial vessels [16].
Variables that could potentially affect the acute infarct
volume were recorded for each patient. These included
sex, age, prior history of hypertension, diabetes, hyperlipi-
demia, valvular heart disease, coronary heart disease, time
from symptom onset to MRI, and medications used before
the onset of stroke including the statins, angiotensin
receptor blockers, antiplatelet agent and warfarin. The
CHADS2 score,[17] which is a simple method of estimat-
ing the risk of stroke in patients with non-rheumatic AF,
was estimated from the clinical data and modified to
correlate the score with stroke phenotype. Five risk factors
are considered when determining the CHADS2 score: (a)
C, recent congestive heart failure, (b) H, hypertension, (c)
A, age ≥ 75 years, (d) D, diabetes mellitus, and (e) S,
history of stroke or transient ischemic attack. In the pre-
sent study, we used prior stroke or transient ischemic
attack instead of the stroke index. In addition, we investi-
gated use of the new CHA2DS2-VASc [18] score system
for predicting the stroke phenotype, including additional
stroke risk factors: (f) V, indicates vascular disease, (g) A,
indicates age between 65-74 and (h) S, indicates sex cate-
gory(female). The National Institutes of Health Stroke
Scale (NIHSS) score on admission was also used to assess
the severity of stroke. Stroke onset time was defined as the
last time the patient was known to be free of symptoms.
All patients underwent routine blood tests and high-sensi-
tivity C-reactive protein (CRP) was taken as the impending
cerebrovascular marker [19,20]. Hemostatic markers of
prothrombotic tendency, including D-dimer and fibrino-
gen, were also evaluated. Patients underwent electrocar-
diography and cardiac telemetry for at least 24 hours to
evaluate the persistence of AF. Paroxysmal AF is defined
as intermittent periods of AF interposed with episodes of
normal sinus rhythm, normally < 7 days [21]. In addition,
echocardiogram was conducted in all but 12 patients who
showed poor cooperation or acute illness owing to medical
conditions or the stroke itself. During the echocardiogram,
the size of the left atrium and left ventricular ejection frac-
tion were measured,[22-25] and the E/e’ ratio and DT
were measured to diagnose the diastolic dysfunction [26].
DWI Infarct volume measurement: Methods and
Image Analysis
DWI was obtained using two levels of diffusion sensiti-
zation (b values of 0 and 1000 s/mm
2;5 - 7m ms l i c e
thickness; no gap). For each patient, the DWI lesion
volumes were automatically outlined with subsequent
manual corrections. The volumes were calculated using a
computer-assisted volumetric analysis program (Medical
Image Processing, Analysis and Visualization, Version
3.0, National Institutes of Health, Bethesda, Md). Raters
outlined regions of acute diffusion abnormality on the b
= 1000 s/mm
2 image while consulting the apparent diffu-
sion coefficient and FLAIR sequences to distinguish
acute from nonacute changes in diffusion. All acute DWI
lesions were defined on a slice-by-slice basis using a
semiautomatic threshold approach by a rater who was
blinded to all clinical information.
Infarct patterns
We divided the patients into three infarct topography pat-
tern groups based on the observed DWI patterns: (a) terri-
torial infarcts involving two or three MCA subdivisions
(superior, inferior, or deep), (b) lobar infarcts involving
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and deep infarcts, and (c) small (< 1 cm in diameter) scat-
tered patterns, suggesting microembolism. Two readers
blinded to the clinical data analyzed the DWI data, and
the interobserver agreement (-value) was 0.92 (P < 0.001)
for interpretation of the DWI lesion pattern (territory vs.
lobar/deep vs. small scattered). The opinion of a third
reader was obtained in cases of disagreement.
Statistical analysis
All numeric data are presented as the mean ± SD or med-
ian (interquartile range [IQR]). The differences in DWI
pattern and infarct volume and the clinical and laboratory
parameters were evaluated by one-way ANOVA with post
hoc analysis using the Fisher’s least-square difference or
Kruskall-Wallis test for continuous variables and Pearson’s
c
2,F i s h e r ’s exact test or linear by linear association for
categorical variables. An independent t-test or the Mann-
Whitney U test was used to evaluate differences in the fac-
tors between the groups. The agreement rate and -value
between the infarct patterns reported by inter-observers
was also obtained. Moreover, multivariate logistic regres-
sion analysis (stepwise method) was conducted to predict
the independent contribution of factors that influenced
stroke phenotypes (territorial pattern or highest quartile
DWI lesion volumes). Variables from univariate analyses
at P < 0.05 were considered to represent the explanatory
variables and the other variables that we were specifically
interested in; age, CHADS2 and CHA2DS2-VASc score
and PT were entered for multivariate analysis. Among
males in the present study, there were 29 current smokers
and 24 ex smokers; however, there were only 2 female
smokers and no female ex smokers. Accordingly, we did
not analyze the impact of smoking on stroke phenotypes.
P values < 0.05 were considered to be statistically
significant.
Results
Among 275 patients who met the inclusion criteria during
the study period, only 27 (9.8%) had appropriate anticoa-
gulation as indicated by an INR above 1.6 [6]. Finally, a
total of 231 patients (118 men and 113 women; age, 70.0 ±
11.1 years) were included in this study. Reasons for exclu-
sion of the remainder of the patients included probable
other etiologies, the presence of large artery disease such
as significant stenosis on ipsilateral carotid bifurcation (ten
patients) and other causes (seven patients).
MRIs were completed within an average of 20.0 ± 28.9
hours of the event (range, 1-72 hours). The DWI lesion
volumes ranged from 0.04-338.6 ml (median -11.86 ml;
IQR, 3.07-44.20 ml). The clinical characteristics of the
patients according to the DWI infarct volume quartile
and infarct patterns are shown in Tables 1 and 2. NIHSS
upon admission was associated with the subgroups of
stroke phenotypes (P < 0.001). No correlation was
observed between the levels of INR and DWI lesion
volumes (r = -0.058, P = 0.495) (Additional file 1).
The vascular risk factor profiles, the CHADS2 and
CHA2DS2-VASc score, had no relationship with either
stroke phenotype (Figure 1). Eighty-two patients (35.5%)
had paroxysmal AF and the others had permanent AF.
Twenty-eight patients were taking warfarin at sub-thera-
peutic levels, while 91 (39.3%) were taking antiplatelet
agents. Interestingly, the prior use of medications includ-
ing antiplatelet agents and warfarin was not related to the
stroke phenotypes. We investigated the use of statin and
angiotensin receptor blockers (ARBs), but data was not
available for about 30% of the patients and the rest the
proportion of the patients who had statins and ARBs was
checked only 14.0%-24.1% and 18.5%-35.7%. Therefore,
we could not evaluate the relationship between that medi-
cations and the stroke phenotype.
Compared with female, male gender was significantly
associated with large infarct volumes (p = 0.036). Addi-
tionally, both systemic and local factors were associated
with stroke phenotypes. Specifically, the lower left ventri-
cular ejection fraction (p = 0.020) and higher D-dimer
(p = 0.035) in patients was significantly associated with the
highest quartile group of the DWI lesion volume, and the
lower left ventricular ejection fraction was observed in
patients with a territorial pattern (p = 0.008). Other vari-
ables showed no relationship with stroke phenotypes.
Multiple logistic regression analysis was conducted to
further evaluate the independent predictors for stroke phe-
notypes; however, systemic, local factors and CHADS2 and
CHA2DS2-VASc score did not significantly add value
of either stroke phenotype. (Additional file 2, Table S1
and S2).
Discussion
Stroke affects not only the person who may be disabled,
but their entire family and other caregivers [27]. In addi-
tion, more than half of the individuals at risk of stroke
view a major stroke as being worse than death [27,28].
Identification of predictors of stroke phenotype and
modification of these factors are particularly important
in patients with AF. Despite recent advances in predict-
ing the occurrence of AF-related stroke, little is known
about the determinants of stroke phenotype in this type
of ischemic stroke.
It was recently reported that the admission INR in pre-
admission warfarin users was inversely correlated with
infarct volume as a result of the formation of a more fra-
gile embolus, earlier recanalization or acceleration of
thrombolysis [7]. In the present study, only 27 (9.8%) of
275 patients had appropriate anticoagulation as indicated
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and since we wanted to identify factors in addition to
INR level that may influence the phenotypic presentation
of stroke, we focused on patients who showed inadequate
anticoagulation. The results of our study indicated that
INR levels below the therapeutic range (< 1.6) were not
correlated with infarct volumes, suggesting that only the
therapeutic range of anticoagulation can modify the
occurrence of stroke and phenotype in patients with AF
[29]. In the present study, 91 (39.3%) patients were taking
antiplatelet agents before admission. The use of antiplate-
let agents before admission was also not related to the
stroke phenotypes in the present study.
We next investigated the association of well-known risk
factors for ischemic stroke and stroke phenotypes in
patients with AF. Among the patients with AF, the abso-
lute risk of stroke varies depending on patient age and
other clinical features (associated stroke risk factors). The
CHADS2 score, which is the clinical prediction rule
for estimating the risk of stroke in patients with nonrheu-
matic AF, is the risk stratification scheme most widely
used to predict AF-related thromboembolism [17]. In the
present study, the CHADS2 and newly revised CHA2DS2-
VASc score were not related to the stroke phenotype.
Moreover, none of the CHADS2 components (e.g. hyper-
tension and congestive heart failure) were associated with
the stroke phenotype. Therefore, the results of the pre-
sent study may indicate that the stroke phenotypes dif-
fered among patients with AF-related stroke, and that the
factors related to the severity of stroke must be different
from the known factors that contribute to the risk of
stroke in AF.
Finally, local and systemic factors may also contribute
to stroke phenotype in AF patients. The thrombi in AF
patients have been strongly and consistently linked to
stasis. Specifically, reduced blood flow velocities in the
Table 1 Demographic and clinical characteristics among the infarct volume quartile groups
Quartile of DWI lesion volumes, ml P
Q1
(< 3.1)
n=5 8
Q2
(3.1-11.8)
n=5 8
Q3
(11.9-44.2)
n=5 8
Q4
(> 44.2)
n=5 7
(Q4 vs. others)
NISS score on admission 4.0 ± 3.9 8.1 ± 6.1 10.8 ± 6.5 15.1 ± 6.8 < 0.001
Vascular risk factors
Age 69.0 ± 10.9 70.0 ± 11.1 72.5 ± 10.4 69.5 ± 11.7 0.547
Male gender 24(41.4%) 26(44.8%) 32(55.2%) 36(63.2%) 0.036
Hypertension 41(70.7%) 41(70.7%) 42(72.4%) 36(63.2%) 0.250
Diabetes 10(17.2%) 13(22.4%) 7(12.1%) 14(24.6%) 0.222
Previous TIA/stroke 18(31.0%) 15(25.9%) 13(22.4%) 13(22.8%) 0.585
CHADS2*score 0.871
0-1 28(48.3.%) 24(41.4%) 25(43.1%) 25(43.9%)
2-3 22(37.9%) 27(6.6%) 28(48.3%) 24(42.1%)
4-5 8(13.8%) 7(12.1%) 5(8.6%) 8(14.0%)
Dysrhythmia
Paroxysmal atrial fibrillation 22(37.9%) 22(37.9%) 20(34.5%) 18(31.6%) 0.476
Concomitant valvular heart disease 5(8.8%) 9(15.5%) 5(8.6%) 5(8.9%) 0.663
Heart rate (/min) 78.1 ± 19.2 82.9 ± 21.6 85.1 ± 21.4 84.2 ± 23.2 0.480
Medications prior to onset
Antiplatelet agents user 26(45.6%) 20(34.5%) 26(47.3%) 19(33.3%) 0.229
Warfarin user 7(12.1%) 9(15.5%) 4(6.9%) 8(14.0%) 0.610
Laboratory findings
D-dimer, mg/dL 1.51 ± 2.85 2.01 ± 3.31 3.45 ± 12.87 2.06 ± 3.35 0.035
Fibrinogen, mg/dL 320.0 ± 83.9 303.0 ± 79.2 335.5 ± 81.9 346.6 ± 100.2 0.122
C-reactive protein, mg/dL 1.13 ± 2.95 0.69 ± 1.78 0.95 ± 2.04 0.80 ± 1.31 0.068
Prothrombin Time, INR 1.07 ± 0.11 1.10 ± 0.12 1.06 ± 0.11 1.06 ± 0.10 0.373
Transthoracic echocardiogram finding
Left ventricular ejection fraction, % 62.1 ± 9.8 59.7 ± 12.4 60.2 ± 8.5 56.1 ± 15.4 0.020
Left atrium size, ml 48.0 ± 8.8 46.5 ± 9.4 47.8 ± 8.6 46.5 ± 7.2 0.660
E/e’ ratio 13.20 ± 6.25 16.76 ± 9.85 13.84 ± 8.06 14.52 ± 9.00 0.839
DT, ms 230.5 ± 153.6 248.3 ± 154.5 207.3 ± 115.8 216.1 ± 114.2 0.925
*In CHADS2, S indicates prior stroke or transient ischemic attack.
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blood stasis in the LAA [6]. Recently, increased diastolic
filling pressure has been found to be associated with a
higher rate of left atrial thrombus in the AF, and these
effects occur partially through blood stasis or impaired
LAA function [30]. However, in the present study, the
left atrial size, left ventricular dysfunction, diastolic dys-
function and the persistence of AF were not indepen-
dently associated with stroke phenotypes. In addition to
local factors (altered flow patterns in the LAA), hyper-
coagulable state, endothelial damage or inflammation,
and platelet activation may all contribute to thrombus
formation in AF [31-36]. In the present study, univariate
analysis revealed that higher D-dimer (a degradation
product of fibrinogen) levels were present in patients
with territorial patterns. These findings reflect factors
associated with thrombin-mediated fibrin formation and
indicate that degradation of fibrinogen may be related to
thrombus characteristics (size and fragility).
Strengths of this study included the consecutive recruit-
ment of a well-phenotyped group of patients who under-
went comprehensive workups, including various
serological markers and echocardiogram. However, the
results of this study should be interpreted with caution
owing to the modest sample size and because all data were
from a single centre. Moreover, endothelial activation and
platelet activation were not assessed in this study. Addi-
tionally, TEE was only conducted in ten patients, while the
other patients showed poor cooperation or acute illness
due to medical conditions or the stroke itself.
Conclusion
Our data showed that the determinants of stroke pheno-
types were different from the predictors of stroke (i.e.,
CHADS2 and CHA2DS2-VASc risk scheme) in patients
with AF who were inadequately anticoagulated. Further
studies of different populations and larger cohorts are
warranted.
Table 2 Demographic and clinical characteristics among infarct pattern groups
DWI lesion patterns P
Territory
n = 46 (19.9%)
Lobar/Deep
n = 118 (51.1%)
Small scattered
n = 67 (29.0%)
(Territory vs. others)
NIHSS score on admission 16.3 ± 6.3 9.6 ± 6.1 4.1 ± 4.2 < 0.001
Vascular risk factors
Age 68.3 ± .12.4 71.6 ± 11.4 69.3 ± 9.3 0.324
Male gender 29(63.0%) 57(48.3%) 32(47.8%) 0.070
Hypertension 28(60.9%) 84(71.2%) 48(71.6%) 0.733
Diabetes 10(21.7%) 20(16.9%) 14(20.9%) 0.603
Previous TIA/stroke 13(28.3%) 25(21.2%) 21(31.3%) 0.636
CHADS2*score 0.684
0-1 21(45.7%) 51(43.2%) 30(44.8%)
2-3 18(39.1%) 55(46.6%) 28(41.8%)
4-5 7(15.2%) 12(10.2%) 9(13.4%)
Dysrhythmia
Paroxysmal atrial fibrillation 15(32.6%) 44(37.3%) 23(34.3%) 0.647
Concomitant valvular heart disease 5(11.1%) 14(12.0%) 5(7.5%) 0.878
Heart rate (/min) 84.2 ± 25.1 84.2 ± 21.0 79.8 ± 19.9 0.501
Medications prior to onset
Antiplatelet agents user 15(32.6%) 45(39.1%) 31(47.0%) 0.246
Warfarin user 8(17.4%) 12(10.2%) 8(11.9.%) 0.221
Laboratory findings
D-dimer, mg/dL 2.37 ± 3.76 1.89 ± 3.19 1.29 ± 2.03 0.105
Fibrinogen, mg/dL 340.72 ± 100.6 324.5 ± 88.0 319.4 ± 77.7 0.230
C-reactive protein, mg/dL 0.84 ± 1.14 0.93 ± 2.22 0.87 ± 2.41 0.041
Prothrombin Time, INR 1.08 ± 0.11 1.07 ± 0.12 1.08 ± 0.10 0.667
Transthoracic echocardiogram finding
Left ventricular ejection fraction, % 55.6 ± 16.3 60.0 ± 10.2 61.1 ± 11.1 0.008
Left atrium size, ml 47.2 ± 7.5 47.8 ± 9.2 46.4 ± 8.1 0.991
E/e’ ratio 14.53 ± 10.21 15.11 ± 9.00 13.71. ± 6.16 0.478
DT, ms 237.4 ± 131.9 215.9 ± 118.9 244.8 ± 163.3 0.317
*In CHADS2, S indicates prior stroke or transient ischemic attack.
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Additional file 1: The association of infarct volume and
international normalized ratio upon admission.
Additional file 2: Table S1. Logistic regression analysis for the highest
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